0.40
-0.0732(-15.63%)
Currency In USD
| Previous Close | 0.47 |
| Open | 0.46 |
| Day High | 0.46 |
| Day Low | 0.39 |
| 52-Week High | 1.82 |
| 52-Week Low | 0.22 |
| Volume | 394,727 |
| Average Volume | 234,665 |
| Market Cap | 11.08M |
| PE | -0.22 |
| EPS | -1.77 |
| Moving Average 50 Days | 0.47 |
| Moving Average 200 Days | 0.81 |
| Change | -0.07 |
If you invested $1000 in NextCure, Inc. (NXTC) since IPO date, it would be worth $19.85 as of July 12, 2025 at a share price of $0.395. Whereas If you bought $1000 worth of NextCure, Inc. (NXTC) shares 5 years ago, it would be worth $48.47 as of July 12, 2025 at a share price of $0.395.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
GlobeNewswire Inc.
Jun 16, 2025 11:05 AM GMT
NextCure gains global rights to SIM0505 excluding greater China, where Simcere Zaiming will retain rightsPhase 1 clinical trial ongoing for SIM0505 in China; U.S. Phase 1 clinical trial is expected to begin in the third quarter of 2025Initial Phase 1
NextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025
GlobeNewswire Inc.
May 29, 2025 8:05 PM GMT
LNCB74 is in a Phase 1, open-label, first-in-human study that will include dose escalation, safety, and biomarker backfills and randomized dose expansion/optimizationThe study is currently enrolling in dose escalationPoster to be presented June 2, 20
NextCure Provides Business Update and Reports First Quarter 2025 Financial Results
GlobeNewswire Inc.
May 01, 2025 8:05 PM GMT
Dosing cohort 3 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in multiple cancers and plan to initiate backfill cohorts in the second half of 2025Plan to provide a proof of concept data readout in the first half of 2026Cash of approximately $55.9 millio